Comparing Canadian and United States opioid agonist therapy policies
- 1 December 2019
- journal article
- research article
- Published by Elsevier BV in International Journal of Drug Policy
- Vol. 74, 257-265
- https://doi.org/10.1016/j.drugpo.2019.01.020
Abstract
No abstract availableFunding Information
- National Institute on Drug Abuse (F30 DA044700)
- European Commission Grant (701698)
- Michael Smith Foundation for Health Research
- St. Paul’s Foundation Scholar award
- National Institute on Drug Abuse (R25-DA037756)
- National Institute on Drug Abuse (UG1 DA015815)
This publication has 27 references indexed in Scilit:
- American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid UseJournal of Addiction Medicine, 2015
- National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted TreatmentAmerican Journal of Public Health, 2015
- The role of Cochrane reviews in informing international guidelines: a case study of using the Grading of Recommendations, Assessment, Development and Evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependenceAddiction, 2014
- Financial Factors and the Implementation of Medications for Treating Opioid Use DisordersJournal of Addiction Medicine, 2012
- Diacetylmorphine versus Methadone for the Treatment of Opioid AddictionThe New England Journal of Medicine, 2009
- Methadone maintenance therapy versus no opioid replacement therapy for opioid dependenceEmergencias, 2009
- French Field Experience with BuprenorphineThe American Journal on Addictions, 2004
- From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United StatesDrug and Alcohol Dependence, 2003
- The Expansion of Methadone Prescribing in Ontario, 1996–1998Addiction Research, 2000